Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Am J Surg Pathol. 2012 Feb;36(2):173–184. doi: 10.1097/PAS.0b013e3182417d36

Table 5.

Molecular abnormalities and median survival in small cell neuroendocrine carcinoma (small cell NEC), large cell neuroendocrine carcinoma (large cell NEC), well-differentiated neuroendocrine tumor (NET) of the pancreas, pancreatic ductal adenocarcinoma (PDAC) and small cell lung carcinoma.

Characteristic Small cell NEC
(present study)		 Large cell NEC
(present study)		 Well-
differentiated
NET		 PDAC Small cell lung carcinoma
KRAS 25% 33% 0%
(present study)		 > 90% 0–10%
p16 11% 50% 0%
(present study)		 80–95% 0–10%
p53 100% 90% 0%
(present study)		 75% 80–90%
Smad4/Dpc4 0% 10% 0%
(present study)		 55% 0%
Rb 89% 60% 0%
(present study)		 13%
(present study)		 80–100%
Bcl-2 100% 50% 18%
(present study)		 20% 75–95%
Median survival 14 months 10 months 99 months 6 months 9–12 months

NEC, neuroendocrine carcinoma; NET, neuroendocrine tumor; PDAC, pancreatic ductal adenocarcinoma.